Finance

Lists
Why is PRLD down 2.88%?
Dive Deeper
PRLD:NASDAQ
Prelude Therapeutics Inc
$3.88
-2.88%
(-0.12) 1D
$4.08
+5.16% (+0.20)
After hours
Closed: Sep 25, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRLD...
Open
$4.00
High
$4.05
Low
$3.83
Mkt. cap
309.24M
Avg. vol.
566.49K
Volume
336.23K
52-wk high
$6.83
52-wk low
$1.15
EPS
-$0.73
Beta
0.97
Shares outstanding
64.92M
No. of employees
79
Open
$4.00
High
$4.05
Low
$3.83
Mkt. cap
309.24M
Avg. vol.
566.49K
Volume
336.23K
52-wk high
$6.83
52-wk low
$1.15
EPS
-$0.73
Beta
0.97
Shares outstanding
64.92M
No. of employees
79
News stories
From web sources and news partners
About Prelude Therapeutics Inc
CEO-
Employees79
Founded2016
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websitepreludetx.com
Analyst ratings
Based on 2 analysts giving stock ratings to PRLD in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PRLD in the last 3 months.
Highest
Current $3.88
$12.00 (+209.68%)
Average
$10.00 (+158.06%)
Lowest
$8.00 (+106.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joyce Zhou
J.P. Morgan
Buy
Initiated
$12.00
+209.7%
09/17/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$12.00
+209.7%
09/17/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$8.00
+106.5%
07/29/2026
Jason Kolbert
D. Boral Capital
Buy
Initiated
$9.00
+132.3%
05/04/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$6.00
+54.8%
03/11/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.14 / -$0.18
+24.32%beat
Revenue / Est. (USD)
5.70M / 0.00
+∞%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6.50M
5.64M
4.58M
5.70M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.71M
16.79M
13.60M
16.13M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.21M
4.90M
5.16M
5.03M
Operating expense
26.92M
21.69M
18.76M
21.16M
Total operating expenses
26.92M
21.69M
18.76M
21.16M
Operating income
-20.42M
-16.05M
-14.18M
-15.45M
Other non operating income
693.00K
891.00K
3.79M
1.53M
EBT including unusual items
-19.72M
-16.46M
-10.38M
-13.92M
EBT excluding unusual items
-19.72M
-15.16M
-10.38M
-13.92M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.72M
-16.46M
-10.38M
-13.92M
Net profit margin
-303.46%
-291.79%
-226.75%
-244.06%
Earnings per share
-0.26
-0.20
-0.13
-0.14
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.99M
-15.63M
-13.79M
-15.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps